1.2021On May 28th, Yuheng Pharmaceutical received the Inquiry Letter on the 2020 Annual Report of Harbin Yuheng Pharmaceutical Co., Ltd. issued by Shenzhen Stock Exchange. The inquiry letter of Shenzhen Stock Exchange pointed out that Yuheng Pharmaceutical was required to specifically analyze the rationality of the company's operating income changes, whether there is a possibility of continuous decline, and fully prompt the relevant risks.
2. The main reason is that at the end of 2020, Yuheng Pharmaceutical had an uncompensated loss of 874 million yuan and paid-in share capital of 26,543.8+0.98 billion yuan, and the company's uncompensated loss exceeded one third of the total paid-in share capital. From 20 18 to 2020, the company's operating income was 5.481billion yuan, 5.054 billion yuan and 3.055 billion yuan respectively, and the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses for two consecutive years was 0.0 1 billion yuan,-259.6 million yuan and-305 million yuan respectively.
1. Yuheng Pharmaceutical Co., Ltd. was established in 2000. Its predecessor was the pharmaceutical factory affiliated to Heilongjiang Rehabilitation Research Institute. Zhu bought it at a price of 1.68 million yuan and changed it to Yuheng Pharmaceutical Co., Ltd. 20 10. Yuheng Pharmaceutical was listed on the small and medium-sized board of Shenzhen Stock Exchange. At the beginning of its establishment, its main product was the orthopedic drug Lugua polypeptide, but the monitoring of this product in recent years and the "bright sword" of the credit evaluation system of the medical insurance bureau this year are suffering from extinction.
2. Since the listing of 20 10, the company has successfully initiated 13 mergers and acquisitions. In contrast, the amount and proportion of the company's investment in R&D are not too large. Through continuous cooperation and acquisition, Yuheng Pharmaceutical's product line covers skeletal muscle, diabetes, cardiovascular and cerebrovascular diseases, vitamins, mineral supplements and other fields.
3. During the reporting period, influenced by the national key drug monitoring catalogue, the sales income of sodium creatine phosphate for injection of Yuheng Pharmaceutical (Laibotong) in 2020 was 65,438+0,246,5438+0 in 370 yuan, which was 74.05% lower than that in the same period of 2065,438+09; However, due to the termination of the agency, the sales revenue of clopidogrel bisulfate tablets in 2020 was 53 10200 yuan, a decrease of 98.63% compared with the same period of 20 19. In 2020, the sales income of sodium creatine phosphate for injection (Weijianeng) was 654.38+088.5553 million yuan, which was 90.89% lower than that of 2065.438+09 in the same period.